Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vitrafy Life Sciences Ltd. ( (AU:VFY) ) has shared an announcement.
Vitrafy Life Sciences has scheduled the release of its Quarterly Activities Report and cash flow statement for the quarter ended 31 December 2025, alongside an investor briefing on 29 January 2026 to present and discuss the results. The briefing, accessible via online registration, underscores the company’s efforts to engage the market and maintain transparency with investors as it advances its cryopreservation technology and service-led business model.
The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.10 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited (ASX: VFY) is a Melbourne-based life sciences company that has developed breakthrough cryopreservation technology aimed at dramatically improving cell survival rates across applications such as blood platelets, cell and gene therapies, aquaculture and bovine reproduction. It delivers complete cryopreservation solutions via a managed service revenue model built around its FDA-registered Smart Freezing and Smart Thawing devices, the integrated LifeChain software platform, and associated Smart Packaging systems.
Average Trading Volume: 36,726
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$117.5M
See more insights into VFY stock on TipRanks’ Stock Analysis page.